Souhaitez-vous accéder aux communiqués récents ?

  The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival...

Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of...

Oslo, February 8, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth...

  Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall...

  Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died.As of today, the 70 events...

Oslo, 4 January 2024: Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 500 shares in the company at an average price of NOK 130.00 per share. Following...

Oslo, 2 January 2024: Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of NOK 119.75 per share. In...

Oslo, 19 December 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at an average price of...

  Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with...

   Oslo, November 28, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that Aitana Peire, Ph.D., has...